Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine. Asleh K, Lluch A, Goytain A, Barrios C, et al. Clin Cancer Res 2022 Nov 8. pii: 710523. doi: 10.1158/1078-0432.CCR-22-2191.

Read + Share

Amedeo Smart

Independent Medical Education

Asleh K, Lluch A, Goytain A, Barrios C, et al. Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine. Clin Cancer Res 2022 Nov 8. pii: 710523. doi: 10.1158/1078-0432.CCR-22-2191.
PMID: 36346687